- $400m MC
- $125m net cash
- Fast-growth businesses: $120m rev run-rate w/ small ebitda loss
- “No-growth” telecom: >$60m FCF run rate
“Sometimes, a free lunch, is free”
Quick and dirty $IDT val.
3x fast-growth rev. + 1/2 net cash + 6x FCF = $800m value. Which is prob on the low side. Vs. $400m MC
$IDT CC:
- Spinoff Net2Phone by year's end
- Telephony doing well - $40-45m FCF for long time
- NRS (POS Terminals & Merchant services):
- TAM in 100's K's of stores - barely scratched
- Will be way more valuable than IDT now
- GM & NM will continue to increase
$IDT CC:
"Penis business doing well" !? ....oh "pinless". OK
I guess market liked earnings. $IDT +15%
$IDT Nice Q3. Even old telephony business is growing. Low-teens P/fcf now. Stock, after >2x ytd, no longer the no-brainer-bargain.
Is $RFL the next Jonas StraightPath-like home run? Two cancer drugs in expedited-FDA-review status for a Q1 decision. Market size for Pancreatic approval alone could 10x the stock. 65%-approval chance each (FDA stats.) More Jonas magic possible? Or could be nothing....
$RFL$22/sh now. $200-$3,000 possible
- if Pancreatic drug approved this quarter (65% odds) & likely becomes standard of care.
- A typical Jonas set up. (I recall Net2phone $ Straightpath.)
With two fast-tracked drugs for FDA approval, 65% chance each this quarter, the EV on this one seems off-the-chart $RFL
Future PLC ( #futr ). Another great UK rollup compounder. 50%-CAGR. Now cheap. But, boy, an ad-based business model now?
Another day, another 50% cagr/share. IDK how #FUTR does it, but they do. 👍H1 results, esp for an ad-based business. Outlook seems fine despite virus. investegate.co.uk/future-plc--fu…
Results are so good vs price, this is either a fraud or a steal. #FUTR